Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes (Q58864229)

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

New approaches in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

CD26, let it cut or cut it down.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Natural substrates of dipeptidyl peptidase IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.13.4.499